IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$66.54 USD
+0.92 (1.40%)
Updated May 29, 2024 04:00 PM ET
After-Market: $66.50 -0.04 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITCI 66.54 +0.92(1.40%)
Will ITCI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Other News for ITCI
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Intra-Cellular participates in a conference call with JPMorgan
Intra-Cellular participates in a conference call with JPMorgan